从随机AMBORA试验到临床实践:口服抗肿瘤治疗用药错误比较
本研究比较随机AMBORA试验干预组(n=98)与真实世界AMBORA中心(n=142)在新口服抗肿瘤药起始治疗时的用药错误。真实世界用药错误频率为试验的两倍(人均0.83±0.80 vs 0.41±0.53,P<0.001),但两组高比例错误被完全解决(85.7% vs 88.3%,ns),错误特征相似。
要点
- 真实世界口服抗肿瘤治疗用药错误频率显著高于随机试验。
- 真实世界方案更复杂、合并用药数更多、ECOG状态更高。
- 临床药理/药学监护项目在真实世界仍能解决高比例用药错误。
核心结论
- 真实临床实践中口服抗肿瘤治疗用药错误比随机对照试验更频繁。
- 临床药理/药学监护项目在真实世界能解决高比例用药错误。
研究设计与样本
- 比较随机AMBORA试验干预组(n=98)与真实世界AMBORA中心(n=142)新口服抗肿瘤治疗起始数据。
主要发现
- 真实世界人均用药错误为0.83±0.80,试验组为0.41±0.53,P<0.001。
- 真实世界方案更复杂、中位合并用药数更高、ECOG状态更高。
- 两组错误完全解决率分别为85.7%与88.3%,差异无统计学意义(ns)。
- 两组用药错误特征(如患者相关原因、药物-药物/药物-食物相互作用)相似。
临床怎么用
- 口服抗肿瘤治疗起始时应开展系统用药审核与药学监护。
- 真实世界患者合并用药多、ECOG状态高,需重点关注用药错误。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The randomized AMBORA trial showed that medication errors are frequent in patients treated with oral antitumor therapeutics and that they can be substantially reduced by an intensified clinical pharmacological/pharmaceutical care program. While randomized controlled trials are essential to generate clinical evidence, their generalizability in real-world is not always given. The AMBORA care program was implemented in clinical routine within the AMBORA Competence and Consultation Center (AMBORA Center) at the Comprehensive Cancer Center Erlangen-EMN, allowing a thorough comparison of medication error frequencies and characteristics. Our primary analysis compared data at therapy initiation of new oral antitumor therapeutics from the AMBORA trial intervention group (n = 98) and the AMBORA Center (n = 142). Medication errors involving the oral antitumor therapeutics were twofold higher in real-world compared to the randomized controlled trial (mean 0.83 ± 0.80 per patient vs. 0.41 ± 0.53, P < 0.001). We observed more complex oral antitumor therapeutic regimens, a higher median number of medications, and a higher ECOG status in clinical routine vs. the randomized trial. A high percentage of medication errors was completely solved in both groups (85.7% vs. 88.3%, ns). Medication error characteristics within the complete medication (oral antitumor therapeutics and concomitant medication) were similar in both groups (e.g., patient-related causes, drug-drug/drug-food interactions). Taken together, medication errors were even more frequent in clinical routine than in the randomized controlled trial and a high rate was solved in clinical routine by a clinical pharmacological/pharmaceutical care program.
引用
- Cuba L, Dürr P, Dörje F, et al. From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy. Clin Pharmacol Ther. 2024. PMID: 38655859. doi:10.1002/cpt.3266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。